United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.

Wall Street analysts reshuffled their bets on energy giants, homebuilders, and emerging space plays on Thursday, and the moves cut in some surprising directions for names investors thought they had figured out.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) are rising in Thursday morning trading following a federal court victory in its patent litigation against competitor Liquidia Corp.

United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics' patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).“We are pleased with the Co.

Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by ​rival United Therapeutics , dealing a major blow to the treatment's ‌commercial outlook.

A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.

United Therapeutics is rated Buy, with a base case valuation of $535/share, despite recent revenue declines driven by competition from Liquidia's Yutrepia. Tyvaso DPI, UTHR's largest and still-growing product, is key; declines are isolated to older formulations, not the core dry powder franchise. Upcoming catalysts include FDA reviews for IPF and Ralinepag, with label expansion and new product launches potentially driving significant upside.